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Abstract
Background: Misfolding and pathological aggregation of neuronal proteins has been proposed to play a critical role in the
pathogenesis of neurodegenerative disorders. Alzheimer’s disease (AD) and Parkinson’s disease (PD) are frequent
neurodegenerative diseases of the aging population. While progressive accumulation of amyloid b protein (Ab) oligomers
has been identified as one of the central toxic events in AD, accumulation of a-synuclein (a-syn) resulting in the formation of
oligomers and protofibrils has been linked to PD and Lewy body Disease (LBD). We have recently shown that Ab promotes
a-syn aggregation and toxic conversion in vivo, suggesting that abnormal interactions between misfolded proteins might
contribute to disease pathogenesis. However the molecular characteristics and consequences of these interactions are not
completely clear.
Methodology/Principal Findings: In order to understand the molecular mechanisms involved in potential Ab/a-syn
interactions, immunoblot, molecular modeling, and in vitro studies with a-syn and Ab were performed. We showed in vivo in
the brains of patients with AD/PD and in transgenic mice, Ab and a-synuclein co-immunoprecipitate and form complexes.
Molecular modeling and simulations showed that Ab binds a-syn monomers, homodimers, and trimers, forming hybrid ring-
like pentamers. Interactions occurred between the N-terminus of Ab and the N-terminus and C-terminus of a-syn.
Interacting a-syn and Ab dimers that dock on the membrane incorporated additional a-syn molecules, leading to the
formation of more stable pentamers and hexamers that adopt a ring-like structure. Consistent with the simulations, under in
vitro cell-free conditions, Ab interacted with a-syn, forming hybrid pore-like oligomers. Moreover, cells expressing a-syn and
treated with Ab displayed increased current amplitudes and calcium influx consistent with the formation of cation channels.
Conclusion/Significance: These results support the contention that Ab directly interacts with a-syn and stabilized the
formation of hybrid nanopores that alter neuronal activity and might contribute to the mechanisms of neurodegeneration
in AD and PD. The broader implications of such hybrid interactions might be important to the pathogenesis of other
disorders of protein misfolding.
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Introduction
Misfolding and pathological aggregation of neuronal proteins
has been proposed to play a critical role in the pathogenesis of
neurodegenerative disorders [1–3]. Dimeric forms of misfolded
proteins can form propagating oligomers [4–6], and aggregates
adopting a globular or protofibrillar shape might represent some of
the toxic species [7]. However there might be a wide heterogeneity
in the size and conformation of the toxic oligomers [6,8].
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the
leading neurodegenerative disorders in the aging population
resulting in dementia and movement disorders. Over 5 million
people live with these devastating neurological conditions in the
US and it is estimated that this country alone will see a 50%
annual increase of AD and PD by the year 2025 [9]. In AD,
amyloid-b protein (Ab)—generated from the proteolytic cleavage
of the amyloid precursor protein (APP)—accumulates in the
intracellular [10–13] and in the extracellular space, leading to the
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fibrillization of a-synuclein (a-syn)—an abundant synaptic termi-
nal protein [15]—results in the formation of characteristic
inclusions denominated Lewy bodies (LBs) [16–21].
Previous studies suggest that in disorders of protein misfolding,
the accumulation of oligomers and protofibrils rather than fibrils
might be the neurotoxic species [22]. While progressive accumu-
lation of Ab oligomers has been identified as one of the central
toxic events in AD leading to synaptic dysfunction [3,6,8],
accumulation of a-syn resulting in the formation of oligomers
and protofibrils that disrupt membrane and mitochondrial activity
has been linked to PD [23–25].
The mechanisms through which Ab and a-syn aggregates might
lead to neurodegeneration are the subject of intense investigation.
Various lines of evidence support the contention that abnormal
aggregates arise from a partially folded intermediate precursor that
contains hydrophobic patches. It has been proposed that the
intermediate oligomers form annular protofibrils and pore-like
structures [1,26–28] that might allow the abnormal flow of ions
such as Ca
2+ [29,30]. Most studies have been focused on studying
the formation of toxic oligomeric species derived from homologous
monomers, however it is possible that heterologous molecules
might also interact to form toxic hybrid oligomers.
For example, we have previously shown that Ab promotes a-syn
aggregation and toxicity in vivo [31], and that Ab and a-syn might
directly interact in vitro [32]. This is of interest because several
studies have now confirmed that the pathology of AD and PD
overlap in a heterogeneous group of conditions denominated
jointly as Lewy body disease (LBD) [19,33–37]. While in patients
with dementia with Lewy bodies (DLB) the clinical presentation is
of dementia followed by parkinsonism, in patients with Parkinson’s
disease dementia (PDD) the initial signs are of parkinsonism
followed by dementia [34,38–40].
Although these studies suggest that interactions between a-syn
and Ab are involved in the pathogenesis of LBD, the molecular
characteristics and consequences of these interactions are not
completely clear. For this purpose, a dynamic model investigating
the early steps of Ab and a-syn co-aggregation was developed
using computer simulations that include the molecular dynamics
(MD) process of protein-protein and protein-membrane docking
with measurements of energies of interaction. These studies were
supported by electron microscopy, in vitro, and in vivo studies in
transgenic (tg) mice to further characterize the nature of Ab and a-
syn interactions.
Our studies suggest that Ab and a-syn interact in vivo [31] and
that at early stages the N-terminal region of Ab monomers and
dimers interact with the N and C-terminus of a-syn, leading to the
formation of pentamers and hexamers with a ring-like structure
[4]. These ring-like aggregates are more stable compared to those
lacking Ab and might correspond to non-selective cation channels
[4]. Thus, better understanding of the steps involved in a-syn
aggregation and the role that Ab plays in this process is important
in order to develop intervention strategies that might prevent or
reverse Ab-mediated a-syn oligomerization and toxic conversion.
Results
a-Syn and Ab directly interact in the brains of patients
with LBD and in APP/a-syn tg mice
Previous studies have shown that Ab plays a key role in
promoting a-syn aggregation [31,32], however it is unclear to
what extent both of these molecules interact in vivo. For this
purpose, immunoblot analysis was performed with brain samples
from cases with LBD and APP/a-syn tg mice. Compared to non-
demented controls and AD cases, in the membrane fractions of the
LBD brain homogenates there was extensive accumulation of a-
syn oligomers including dimers, trimers, pentamers and higher-
order aggregates (Figure 1A,B). Similarly, in the APP/a-syn
double tg animals, which produce high levels of Ab, there was a
significant increase in the levels of a-syn oligomers compared to
single tg and non-tg controls (Figure 1D,E).
To further investigate whether Ab and a-syn might interact in
vivo, co-IP studies were performed. When samples from human
brains were immunoprecipitated with an antibody against Ab and
then analyzed by western blot with an antibody against a-syn, the
strongest interaction was observed in the LBD cases and to a lesser
extent in the AD samples but no interaction was detected in the
non-demented controls (Figure 1C, upper panel). Moreover,
when the brain samples were immunoprecipitated with an
antibody against a-syn and then analyzed by western blot with
an antibody against Ab, a strong band was detected in the LBD
cases followed by the AD cases, but not in the control samples
(Figure 1C, lower panel). Similarly, when brains from the tg mice
were immunoprecipated with an antibody against Ab and then
analyzed by western blot with an antibody against a-syn, the
strongest interaction was observed in the in the APP/a-syn tg
samples but not in the single tg mice or in the nontg controls
(Figure 1F, upper panel). Moreover, immunoprecipitation of the
mouse brain samples with an antibody against a-syn, followed by
immunoblot analysis with an anti-Ab antibody showed a strong
interaction in the APP/a-syn tg but not in the single tg mice
(Figure 1F, lower panel).
Molecular dynamics studies show that Ab and a-syn form
hybrid ring-like structures
To better understand the molecular interactions between Ab
and a-syn that lead to aggregation, we first investigated using
molecular dynamics techniques the conformational changes that
Ab and a-syn undergo over time when docked to a membrane.
Simulation of a-syn was performed based on the micelle-bound
structure of a-syn as resolved by NMR, presuming that a molecule
in the conformation formed in contact with the lipid surface was
disconnected and surrounded by water molecules. These simula-
tions have been previously described [4]. Simulation of Ab was
conducted using the mostly helical existing NMR structure of the
Ab1–42 peptide. The mostly helical structure of Ab is divided into
two regions (termed helix-N and helix-C) connected by a short
linker (Figure S1). In our baseline model, the two curved helical
domains formed an angle of 55u that decreased to around 34u
during the first 0.5 ns of the simulation, and then increased to 52u–
55u during 1.0–1.5 ns of simulation. At 2 ns the angle was at 37u,
at 2.5 ns it was at 28u, and at 3 ns the angle increased to 46u.
During the simulation (Figure S1), the linker loop between the
two helical domains became larger with only two of the initial five
turns of the helix remaining after 3 ns of simulation.
Further analysis consisted of determining changes in the
secondary structure of Ab over time. After 500 ps of simulation,
a coiled region appeared, interrupting the C-terminal a-helix
around amino acid (aa) residue 32. Beginning at 800 ps, turns
appeared in the C-terminal a-helical structure around aa 27, then
after 1 ns this entire region was transformed into an unstructured
loop. The p-helix transformation of the a-helical structure
increased consistently over time (Figure S2).
Since previous studies have suggested that the assembly of a-syn
and Ab oligomers might involve interactions with the membrane
[26], we conducted docking of a-syn (4 ns) and Ab (2 ns)
conformers on a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho-
line (POPC) membrane with a grid cell of 1A ˚. Based on the MD
Hybrid Oligomers in AD/PD
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performed by docking the structure of the 2 ns Ab conformer to
the 4 ns a-syn dimers (Figure 2A) and trimers. This study showed
that the Ab conformers formed complexes with the a-syn dimers
and trimers and had the capability of docking on the membrane
(Figure 2B). Most of the interactions predicted by this model
occurred between the N-terminus of Ab with the N-terminus of
the a-syn molecules, however interactions with the C-terminus of
a-syn were also identified (Figure 2C,D). The interactions of the
Ab conformer (2 ns) in the complex were divided into three groups
reflecting the individual contacts of the Ab molecule with each of
the a-syn molecules in the complex (Figure 2C). For the first
group, the negatively-charged GLU3 of Ab interacts with the
positively-charged LYS6 of the second a-syn molecule (a-syn2),
and GLN15 of Ab most probably creates an H-bond with LYS97
in the middle region of a-syn2 (Table 1 and Figure 2D). For the
second group, the Ab conformer also largely interacts with the N-
terminal part of the first a-syn conformer (a-syn1). Here, LEU17
of Ab contacts LYS32 of a-syn1, PHE19 of Ab creates
hydrophobic contacts with VAL3 and PHE4 of a-syn1, ILE31
of Ab contacts THR22 of a-syn1; and ALA42 of Ab contacts
THR33 of a-syn1 (Table 1 and Figure 2D). Finally, for the third
group, the Ab conformer might also contact the third a-syn
molecule part of the complex (a-syn3) creating possible electro-
static interactions between the LYS5 of Ab and GLU123 of a third
a-syn molecule. The MD simulations demonstrated that over time,
these hydrophobic and electrostatic interactions were stable as
reflected by the distance between the aa residues, which ranged
from 2.8 to 6.8 A ˚ (Table 1). Further molecular simulations
showed that docking of the Ab molecule to the a-syn dimer or
trimer stabilized the complex and facilitated the docking of
additional a-syn monomers resulting in the formation of
pentamers and hexamers of a-syn arranged in a ring-like
conformation (Figure 2E).
Structural organization and energy of interaction of the
hybrid Ab and a-syn oligomers on the membrane
Since previous studies have suggested that the assembly of a-syn
and Ab oligomers might involve interactions with the membrane
[26,41,42], we conducted docking of a-syn (4 ns) and Ab (2 ns)
conformers on a POPC membrane with a grid cell of 1A ˚,
including the membrane in calculations. First, the a-syn molecules
were docked to the membrane to determine the most favorable
energy of interaction for the dimers, trimers and higher-order
oligomers. Then, to each of the a-syn oligomers, an Ab molecule
(2 ns conformer) was docked, selecting the complexes with the
Figure 1. Immunoblot and co-immunoprecipitation analysis of aggregated a-syn in brains of LBD cases and tg mice. (A, B)
Representative western blot (A) and semi-quantitative analysis (B) of levels of a-syn dimers and oligomers in membrane fractions from the frontal
cortex of age-matched non-demented control, AD and LBD brains. In cases with LBD there was a significant increase in the levels of a-syn dimers and
oligomers when compared to controls. (C) Immunoprecipitation of homogenates from control, LBD and AD cases with monoclonal antibodies
against Ab (upper panel) or a-syn (lower panel). Immunoblots were probed with monoclonal antibodies against a-syn (upper panel) or Ab (lower
panel). Ab and a-syn pure proteins were included on the immunoblots as positive controls (first and second lanes). (D, E) Representative western blot
(D) and semi-quantitative analysis (E) of levels of a-syn dimers and oligomers in the membrane fractions from nontg, APP tg, a-syn tg, and APP/a-syn
double tg brains. In APP/a-syn tg mice there was a significant increase in the levels of a-syn dimers and oligomers when compared to nontg or single
tg animals. (F) Immunoprecipitation of brain homogenates from nontg, APP tg, a-syn tg, and APP/a-syn double tg animals with monoclonal
antibodies against Ab (upper panel) or a-syn (lower panel). Immunoblots were probed with monoclonal antibodies against a-syn (upper panel) or Ab
(lower panel). Bar graphs represent the mean of n=4 cases per group. *P,0.05 compared to control human brains or nontg mouse brains (by one-
way ANOVA with post-hoc Tukey-Kramer test).
doi:10.1371/journal.pone.0003135.g001
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These simulations showed that Ab increased the stability of the
oligomers and facilitated further docking of other a-syn molecules
to form pentamers and hexamers on the membrane
(Figure 3A,B). The a-syn complexes that included Ab displayed
higher stability on the membrane and lower electrostatic energy of
interaction when compared to multimers containing only a-syn
(Figure 3B). Both Ab monomers and dimers increased the
stability of the a-syn complexes, with lower electrostatic energy of
interaction of a-syn with the a-syn–Ab monomer and a-syn–Ab
dimer complexes than with the single a-syn molecule (10–15%
higher) (Figure 3B and Figure S3). The hybrid a-syn-Ab
multimers formed ring-like structures that became embedded in
the simulated membrane (Figure 3C,D) after relatively short
(350 ps) MD simulations of the membrane-proteins complex.
During extended simulation times, the a-syn pentamer embedded
progressively further into the membrane, reaching a depth of 1.6A ˚
in the membrane by 800 ps (Figure 3C,D). Space-filled modeling
also demonstrated that the complex containing Ab and the a-syn
pentamer embedded into the membrane over time (Figure 3E,F).
To further investigate the potential interactions between a-syn
and Ab when the two molecules are located on the opposite sides
of a membrane, we performed additional MD simulations where
the 2 ns conformer of Ab was docked on one side of the
membrane, while the 4.5 ns conformer of the a-syn monomer was
docked on the other side of the membrane. During the initial stage
of the MD (at 1.0 ns), Ab was in contact with the membrane at aa
residues 20–33 and was embedded into to the membrane at a
depth of 3A ˚ (Figure 3G). In this orientation, residues 20–33
exhibit a ‘‘membranephilic’’ combination of hydrophobic and
charged residues. The hydrophobic residues in this region
interacted with the membrane by penetration into the hydropho-
bic parts of the lipids. During MD simulations, Ab changed its
overall orientation so that the longer N-terminal a-helix becomes
more perpendicular to the membrane. During the penetration
time (2.3 ns) the C-terminal a-helix of Ab transformed to a p-helix
(Figure 3G), with residues 29–34 forming the tip of the
penetrating peptide. After 2.3 ns of MD simulation, the N-
terminal region of a-syn also penetrated the membrane at a depth
of 1.6A ˚ where the two molecules came into contact with each
other. It worth noting that residues GLY29, ALA30, ILE31,
ILE32, GLY33, and LEU34 created a defined ‘‘hydrophobic
frontal tip for penetration’’ as these residues can better interact
with the hydrophobic parts of the lipid bilayer. Taken together,
these simulation studies support the possibility that even if a-syn
and Ab might be on opposite sides of a membrane, because of
their helical structures and lipid interactions they might be able to
penetrate and interact at an intermediate membrane point.
Figure 2. Molecular dynamics studies of the interactions of one Ab monomer with membrane-docked a-syn multimers. (A)
Diagrammatic representation of the complex formed between the 2 ns Ab conformer and the 4 ns a-syn dimer, composed of two molecules of a-syn
(a-syn1 and a-syn2). (B) Molecular modeling of the Ab monomer/a-syn dimer complex docked to the membrane. (C) Diagrammatic representation of
predicted interactions between the Ab monomer and the two a-syn molecules occur primarily between the N-terminus of Ab and the N-terminus of
the a-syn molecules (circled regions). (D) Specific residues involved in interactions between the Ab monomer and the two a-syn molecules. (E)
Docked complex of Ab and the a-syn dimer or higher-order oligomers (trimer, pentamer) form a ring-like structure on the membrane.
doi:10.1371/journal.pone.0003135.g002
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initial dimer and its docking to the membrane
Recent studies have shown that during the aggregation of a-syn,
formation of essentially static dimeric species is the critical first step
of the aggregation process [43], and a-syn dimers are formed
before other higher-order oligomers [44]. Furthermore, under
certain pathological conditions, dimer formation is the rate-
limiting step in a-syn aggregation [45]. Additional evidence shows
that during the early phase of a-syn aggregation, a high-affinity
lipid binding intermediate is formed [46], and dimers preferen-
tially bind lipid membranes [42]. Moreover, a previous study
showed that in a cell culture model, a-syn forms small oligomers,
primarily dimers and trimers, that preferentially associate with cell
membranes [47]. In support of these results, we have previously
shown that the ‘‘initial’’ a-syn dimer that supports further
aggregation is docked on the membrane in a head-to-head
conformation [4]. This dimer can serve as the core for the
formation of pentameric and hexameric oligomers with a ring-like
organization. In the previous section it was shown that Ab can
bind to this initial a-syn dimer with favorable interaction energies
(Figure 3B). Such electrostatic and van der Waals energy
calculations are useful for defining the proper docking position,
but these are not sufficient to evaluate the possible impact of such
docking to the configuration changes of the a-syn dimer in the
membrane over time. To answer this question, two sets of MD
calculations in the membrane were conducted. The first was
performed with the initial a-syn dimer alone, and the second with
the same complex that included the 2 ns conformer of Ab. The
simulations showed that after 0.8 ns the N-terminal helices of the
a-syn dimer changed their conformation and compromised the
docking plane of a-syn to the membrane surface (Figure 4A,B).
As a parameter that might represent such conformational changes,
the angle between the C-alpha atoms of the residues VAL66 (a-
syn1), LYS45 (a-syn1), VAL37 (a-syn2) was measured to estimate
the possible surface of the protein’s membrane contact plane
(Figure 4A,B,E,F). Based on the calculations for the electrostatic
energy of interactions, an angle of less than 80u allowed stable
docking of the a-syn dimer to the membrane. In contrast, when
the angle was greater than 80u, docking of the a-syn dimer over
the time course of the MD simulations was less likely. For the a-
syn dimer (without Ab), this angle remained close to 80u for up to
0.5–0.8 ns (Figure 4A,E,F), however after this time the angle
increased, compromising the docking of the a-syn dimer to the
Table 1. Ab contact points with a-syn dimer during MD simulations.
Contact 0 ns 0.1 ns 0.5 ns 1.0 ns Interaction
Ab residue a-syn1 residue a-syn2 residue
GLU3* LYS6* 6.2 6.5 6.0 2.8 Electrostatic
PHE4* ILE88* 3.9 3.6 Hydrophobic
ARG5 ILE88 4.2 6.5 Hydrophobic
ASP7 THR92 2.8 6.9 Hydrophobic
GLU11* LYS97* 2.8 2.8 4.8 Electrostatic
VAL12* LYS97* 4.7 4.2 4.8 Hydrophobic
VAL12* VAL95* 3.6 6.1 4.7 Hydrophobic
VAL12* ALA91* 3.8 4.1 Hydrophobic
HIS13 LYS32 4.2 3.6 3.7 Hbond
GLN15 LYS97 4.6 2.8 Hbond
GLN15 GLU105 5.7 6.5 6.5 Possible Hbond
LYS16* ASP98* 4.7 2.8 2.8 2.8 Electrostatic
LYS16* GLU28* 5.5 Electrostatic
LEU17 LYS32 4.8 4.0 5.7 6.4 Hydrophobic
PHE19 PHE4 4.7 4.6 Hydrophobic
PHE19 VAL3 5.4 4.0 Hydrophobic
ILE31 GLY25 5.3 4.4 6.3 Hydrophobic
ILE31 ALA29 5.4 Hydrophobic
ILE31 THR22 6.8 Hydrophobic
ILE31 LYS21 5.6 6.0 Hydrophobic
ILE32 VAL26 6.8 4.7 4.9 Hydrophobic
ILE32 THR22 4.1 4.0 Hydrophobic
LEU34 GLU28 3.8 4.1 4.4 Hydrophobic
LEU34 ALA29 3.8 4.4 4.5 4.1 Hydrophobic
GLU37 ALA29 6.2 4.5 4.3 Hydrophobic
GLU38 ALA29 4.4 Hydrophobic
ALA42 THR33 3.8 Hydrophobic
*Indicates residues located at the points predicted to be critical for stabilization of the Ab-a-syn complexes on the membrane. These resides of Ab were mutated for
additional analysis of Ab-a-syn interactions.
doi:10.1371/journal.pone.0003135.t001
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the initial a-syn dimer, this angle remained within 60u to 80u,
stabilizing the a-syn dimer and allowing the docking of the
complex to the membrane over a longer period of time
(Figure 4C–F).
Next, to determine which residues of Ab were the most critical
to the stabilization of the a-syn dimer during the course of the MD
studies, additional simulations were performed with mutated forms
of the full-length Ab molecule. Inter-molecular interactions that
remained stable over the course of the MD simulations were those
between amino acids that formed electrostatic contacts between
residues with opposite charges such as GLU3 (Ab) and LYS6 (a-
syn2), and LYS16 (Ab) and ASP98 (a-syn2) (Table 1). Other
strong but less stable contacts were the electrostatic interactions
between GLU11 (Ab) and LYS97 (a-syn2), and hydrophobic
interactions between VAL12 (Ab) and VAL95 (a-syn2), and
PHE19 (Ab) and PHE4 (a-syn1) (Table 1), where a-syn1 is to the
left (depicted in magenta) and a-syn2 is to the right (depicted in
brown) in the dimer (Figure 2A). Remarkably, when the MD
simulations were performed with the initial a-syn dimer and a
mutated Ab molecule (PHE4SER, GLU11ARG, VAL12SER,
LYS16ASP), the stability of the dimer docking over time was
compromised, with the angle increasing to greater than 80u after
0.7 ns of the MD simulation (Figure 4F).
Ab and a-syn form hybrid ring-like structures in an in
vitro cell-free system
In the brains of patients with AD and LBD both monomeric
and oligomeric forms of a-syn and Ab may be present, however it
is unclear if the interactions leading to aggregation are only
between monomers or also between monomers and oligomers.
The MD simulations and the electrostatic energy calculations
suggest that in addition to the interactions between monomers and
dimers, interactions between oligomers are also possible. To
investigate this possibility, aggregated or freshly-solubilized Ab and
a-syn were co-incubated and analyzed by immunoblot. Consistent
Figure 3. Modeling and energies of interaction between Ab and a-syn oligomers docked on the membrane. (A) Conformation of
lowest-energy complex between a-syn pentamer and 2 ns Ab conformer on the membrane. (B) Calculated values for the most favorable energies of
interaction between one Ab monomer and an a-syn monomer, dimer, trimer, tetramer or pentamer. Compared to a-syn homomeric species
composed of the same number of a-syn molecules, hybrid Ab/a-syn multimers were more stable and had more favorable (lower) electrostatic
energies of interaction. (C, D) Hybrid Ab/a-syn multimers formed ring-like structures that embedded in the membrane after 350–800 ps of
simulation. (E) Space-filled model of Ab (orange)/a-syn (gray) multimer embedded in the membrane (green) at a depth of 1.6A ˚ after 800 ps of MD
simulation. (F) Space-filled model of Ab (orange)/a-syn (gray) multimer showing the depth of 1.6A ˚ (purple) that the complex embedded into the
membrane (POPC) after 800 ps of MD simulation. (G) Space-filled model of Ab (green) and a-syn (red) monomer initially situated on opposite sides of
the POPC membrane showing penetration of the Ab and a-syn molecules into the membrane and interaction between the two after 2.3 ns of MD
simulation.
doi:10.1371/journal.pone.0003135.g003
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the aggregation of soluble a-syn in an in vitro cell-free system in a
dose and time-dependent manner (Figure S4). In order to
investigate the conformational change of these proteins, immuno-
blot analyses were performed with aggregated and freshly-
solubilized Ab and a-syn co-incubated under comparable
conditions (Figure 5A,B). This study showed that solubilized
Ab induced aggregation of a-syn into tetramers and higher-order
oligomers with changes in electrical charge, suggesting that Ab
induced conformational change in a-syn (Figure 5A). Pre-
aggregated Ab promoted the formation of stable dimers and
trimers of a-syn and, to a lesser extent, higher-order aggregates
(Figure 5A). By immunoblot, freshly-solubilized Ab appeared
mostly as a single band at a molecular weight of 4 kDa, and
aggregated as a series of immunoreactive bands consistent by with
the expected molecular weight of dimers, trimers and tetramers
(Figure 5B). Next, in vitro binding assays were performed to verify
if a-syn and Ab directly interact in the in vitro cell-free system. For
this purpose, the a-syn and Ab protein complexes were
immunoprecipitated with a polyclonal anti-a-syn antibody,
followed by immunoblot analysis with a monoclonal anti-a-syn
antibody or anti-Ab antibody. Western blot analysis demonstrated
that a-syn in the mixture was precipitated by the antibody
(Figure 5C). Co-immunoprecipitated Ab was detected in the
presence of a-syn but not in the absence of a-syn (Figure 5D),
supporting the notion that a-syn and Ab directly interact.
To determine if the Ab residues identified by the simulations as
critical to stabilizing a-syn dimers on the membrane and promoting
further aggregation of a-syn, an additional experiment was
performed with a mutated N-terminal fragment of Ab (18 aa in
length). For this purpose, recombinant a-syn was incubated with a
mutated Ab peptide where positively-charged residues were
substituted for negative ones and hydrophobic residues for
hydrophilic ones (PHE4SER, GLU11ARG, VAL12SER, LY-
S16ASP). Immunoblot analysis confirmed that while the peptide
corresponding to the wild type N-terminal 18 aa sequence of Ab1–42
promoted a-syn aggregation like the full-length Ab1–42 peptide, the
mutated version of the Ab peptide was less effective (Figure 5E,F).
Ab enhances the formation of a-syn ring-like structures
and increases ion conductance alterations
Previous studies have shown in vitro that Ab [48] and a-syn
aggregates can independently form oligomers with a ring-like
morphology [25,49]. However the ultrastructural characteristics of
the hybrid Ab and a-syn multimers are unclear. Consistent with
the MD simulations and the immunoblot analysis, electron
microscopy studies showed that compared to the vehicle control
(Figure 6A), when incubated separately for 6 hrs, Ab and a-syn
generated ill-defined globular structures ranging in size between 5
to 10 nm (Figure 6B,C). In contrast, at 6 hrs the mixture
between Ab and a-syn resulted in well-defined ring-like structures
measuring 9–15 nm with a central channel of approximately 3–
5n m ( Figure 6D). The mixture of Ab and a-syn showed
increased numbers of ring-like structures after 6 hrs (Figure 6E).
At longer periods of incubation, Ab and a-syn alone, and the
mixture formed fibrils of approximately 11 nm in diameter that
increased in number in the samples containing a mixture of Ab
and a-syn (Figure 6F–I).
Since MD simulations were performed in a membrane-based
model, in order to determine if similar interactions occur between
Ab and a-syn in the presence of organic lipids, ultrastructural
studies were performed on cell-free protein preparations that were
incubated with lipid monolayers for 6 hrs. Electron microscopy
analysis confirmed that in the presence of lipids, both Ab
(Figure 6K) and a-syn (Figure 6L) alone form ring-like
structures measuring approximately 5–8 nm in diameter com-
pared to vehicle control (Figure 6J), while in the samples
containing a mixture of Ab and a-syn, this effect was enhanced
(Figure 6M). This suggests that membrane-like lipids facilitate the
formation of Ab/a-syn hybrid ring-like structures.
Since previous studies have suggested that the a-syn ring-like
structures might form pores in the membrane that could be
responsible for the neurotoxic effects of a-syn oligomers
[25,26,28,30], we investigated whether abnormally high levels of
ion currents are detected in cells over-expressing a-syn and if this
process might be enhanced by Ab. For this purpose, we recorded and
compared whole-cell cation currents in human embryonic kidney
(HEK) 293T cells transduced with lentiviral (lenti) vectors expressing
a-syn or green fluorescent protein (GFP) as a control in the presence
or absence of Ab (Figure 7). Immunoblot analysis confirmed that
cells expressed comparable levels of a-syn (Figure 7A). Double-
labeling verified that in co-transduced cells, GFP was also expressed
with a-syn (Figure 7B). The target cells (displaying green
fluorescence) for electrophysiological measurements were identified
by co-transduction with the lenti-GFP vector (Figure 7B).
Figure 4. Molecular dynamics of conformational changes of
membrane-associated a-syn in the presence of one Ab
monomer. (A) Initial conformation of a-syn dimer on the membrane
without Ab.( B) 0.8 ns conformation of a-syn dimer on the membrane
without Ab.( C) Initial conformation of a-syn dimer on the membrane
with Ab monomer. (D) When complexed with the Ab monomer, after
0.8 ns the conformation of the a-syn dimer on the membrane is drawn
closer to the membrane, and the a-syn molecules make more contact
points with the membrane surface than the a-syn dimer alone. (E)
Comparison of the two complexes at 0.8 ns demonstrating the angle
measured between the C-alpha atoms of the residues VAL66 (a-syn1),
LYS45 (a-syn1), VAL37 (a-syn2). The complex without Ab had an angle
of ,80u (upper), while the complex with Ab had an angle of .80u
(lower) and was more stable on the membrane. (F) Changes in angle
measurements in the complexes over time without Ab or in the
presence of wild-type or mutated full-length Ab. In the mutated Ab
peptide, positively-charged residues were substituted for negative ones
and hydrophobic residues for hydrophilic ones (PHE4SER, GLU11ARG,
VAL12SER, LYS16ASP).
doi:10.1371/journal.pone.0003135.g004
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cells from a holding potential of 250 mV to a series of test
potentials ranging from 280 mV to +80 mV in 20-mV incre-
ments. When compared to baseline conditions (i.e., cells infected
with an empty vector or with lenti-GFP), the amplitude of currents
was increased in cells expressing a-syn and treated with vehicle as
well as in cells transduced with an empty vector and treated with
Ab (Figure 7C,D). Moreover, the amplitude of currents in a-syn-
transduced cells treated with Ab was much greater than that in a-
syn-transduced cells treated with vehicle and in vector-transduced
cells treated with Ab (Figure 7C,D). The current amplitude at
+80 mV was 374.6625.5 pA in cells transduced with an empty
vector (n=10), 1467.76152.2 pA in a-syn-expressing cells
(P,0.001 vs. vector control), 2172.76126.8 pA in vector cells
treated with Ab (P,0.001 vs. vector control; P,0.01 vs. a-syn-
expressing cells), and 3640.36824.6 in cells transduced with a-syn
and treated with Ab (P,0.001 vs. vector control; P,0.05 vs. a-
syn-expressing cells) (Figure 7C,D).
Recent studies have shown that the a-syn oligomers might
increase the influx of calcium [30,50]. Thus, it is possible that in
our model the hybrid a-syn and Ab complexes might also promote
cellular dysfunction via abnormal influx of calcium. To investigate
this possibility, levels of intracellular calcium were determined with
the fluorescent calcium indicator Fluo-4. Compared to cells
infected with a control lentiviral vector, the a-syn-expressing cells
displayed a two-fold increase in intracellular calcium. Similar
effects were observed in un-infected cells treated with Ab. The a-
syn-expressing cells treated with Ab displayed an even greater
increase in calcium levels compared to controls (Figure S5).
Taken together, these data indicate that Ab and a-syn form
functional cation nanopores that might lead to cellular dysfunction
by calcium influx.
Discussion
Previous studies have focused on understanding the formation
of toxic oligomeric species derived from homologous monomers.
In the present study we show for the first time that heterogeneous
proteins can form toxic hybrid oligomers. Here we demonstrate
that Ab and a-syn directly interact in vivo and in vitro. Supporting
these findings, Ab and a-syn co-immunoprecipitated in the brains
of patients with LBD as well as in double APP/a-syn tg mice.
Furthermore, molecular modeling studies showed that these
interactions promoted the formation of highly stable ring-like
oligomers composed of both Ab and a-syn and dock in the
membrane. Similarly, in vitro studies confirmed that both freshly-
solubilized as well as aggregated Ab and a-syn can directly interact
and form hybrid ring-like structures.
These findings are consistent with a previous study utilizing a
different line of APP tg mice that showed that Ab promotes the
aggregation of a-syn in vivo and worsens the deficits in a-syn tg
mice [31]. Moreover, a-syn has also been shown to accumulate in
the brains of APP tg [51] and APP/presenilin-1 (PS1) double tg
mice that produce large amounts of Ab [52]. More importantly,
several studies have now shown that in the brains of LBD patients,
Ab contributes to the levels and state of a-syn aggregation and LB
formation [19,32,53–57]. Taken together, these studies in tg mice
and human brains support the contention that Ab and a-syn
interact in vivo and that these interactions are of significance in the
pathogenesis of the disease.
Ab might promote a-syn aggregation by directly interacting
with a-syn molecules bound to the membrane and therefore
facilitating the formation of more stable oligomers. However, Ab
might promote a-syn aggregation through other pathways,
including increased oxidative stress, calpain activation with C-
terminal cleavage of a-syn [58,59] and aberrant phosphorylation
induced by secreted forms of Ab. Under physiological conditions,
Figure 5. Interactions between Ab and a-syn in an in vitro cell-
free aggregation model. Freshly-solubilized or pre-aggregated Ab1–
42 was incubated at concentrations of 10 or 20 mM (as indicated) with
freshly-solubilized recombinant a-syn and samples were analyzed by
immunoblot or co-immunoprecipitation. (A) Increased levels of a-syn
high-molecular weight forms aggregates in the presence of freshly-
solubilized or pre-aggregated Ab, as shown by immunoblot analysis
with a polyclonal antibody against a-syn. (B) Formation of Ab multimers
after incubation under aggregating conditions. (C, D) In vitro binding
assay for Ab and a-syn. Immunoprecipitation of cell-free aggregated
samples was performed using a polyclonal antibody against a-syn.
Immunoblots were probed with monoclonal antibodies against a-syn
(C)o rA b (D). Ab was only detected in samples that were incubated
with a-syn, and in cases where no recombinant protein was included
(negative control), no immunoreactivity was detected with either
antibody. (E, F) Samples containing freshly-solubilized a-syn were
incubated with the following peptides: an 18-mer N-terminal fragment
of Ab containing mutations at the residues determined to be critical for
interaction with a-syn (Ab mut), an 18-mer N-terminal fragment of Ab of
the wild-type sequence (Ab wt), or full-length Ab1–42 peptide (Ab 1–42)
and analyzed by immunoblot with an antibody against a-syn.
Incubation with the Ab mut resulted in lower levels of the dodecamer
form of a-syn. The sequence of the wt and mut Ab peptides (18-mers)
used for these experiments are shown in panel e. Arrows indicate
mutated residues.
doi:10.1371/journal.pone.0003135.g005
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endoplasmic reticulum and in endosomes [60,61]. Similarly,
monomeric a-syn is primarily found in the cytosolic fraction
[15] and is loosely associated with synaptic vesicles [62–64] where
it might play a role in neurotransmitter release. Moreover,
monomeric a-syn can be found in lipid rafts, which is required for
the synaptic localization of a-syn [62]. However, under patholog-
ical conditions, both aggregated Ab and a-syn might associate with
Figure 6. Electron microscopy analysis of hybrid oligomers and fibrils of Ab and a-syn. In vitro cell-free preparations of vehicle, Ab alone,
a-syn alone, or Ab and a-syn were incubated for 6 hrs or 48 hrs and prepared for electron microscopy analysis. (A–D) After 6 hrs of incubation,
compared to vehicle alone (A), Ab (B) and a-syn (C) alone formed globular structures of 5–10 nm in diameter, while incubation of Ab and a-syn
together (D) resulted in the formation of larger, well-defined ring-like structures with a central channel. (E) Analysis of numbers of ring-like structures
formed after 6 hrs incubation. (F–I) After 48 hrs of incubation, compared to vehicle alone (F), Ab (G) and a-syn (H) alone or in combination (I) formed
fibrils of about 11 nm in diameter. (J–M) After 6 hrs incubation in the presence of lipid monolayers, compared to vehicle alone (J), Ab (K) and a-syn
(L) alone formed globular structures of 5–8 nm in diameter, while incubation of Ab and a-syn together (M) resulted in enhanced formation of larger,
well-defined, ring-like structures. Scale bar, 10 nm (A–D, J–M); 100 nm (F–I).
doi:10.1371/journal.pone.0003135.g006
Figure 7. Electrophysiological analysis of the cellular effects of hybrid Ab/a-syn multimers. 293T cells were infected with lenti-a-syn and
lenti-GFP and treated with Ab and analyzed by electrophysiology. (A) Immunoblot analysis showing expression levels of a-syn and GFP in treated
cultures. (B) Immunocytochemical analysis demonstrating high efficiency of infection and co-localization between a-syn and GFP. (C, D)
Representative currents (C) elicited by depolarizing the cells from a holding potential of 250 mV to a series of test potentials ranging from 280 mV
to +80 mV, and corresponding current voltage-relationship curves (D), in a-syn-expressing cells treated with vehicle (a-syn, n=5), vector-transfected
cells treated with Ab (Ab, n=5), and a-syn-expressing cells treated with Ab (a-syn+Ab, n=6).
doi:10.1371/journal.pone.0003135.g007
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specialized domains in the membrane are rich in cholesterol and
sphingolipids and have been proposed to play a role in integrating
signaling pathways [72–75]. Under pathological conditions, lipid
rafts in the membrane have been postulated to play a role in
oligomerization of misfolded proteins [66,67,76] including a-syn
[62,70,71] and Ab [65–67] and might represent a suitable site for
the abnormal interactions between aggregated forms of a-syn and
Ab. In addition, these interactions might occur in other organelles
such as mitochondria, multivesicular bodies and lysosomes since
aggregated forms of Ab and a-syn have been independently
described in these membranous structures [23,77–79]. Alterna-
tively, given the role of lipid rafts in the synaptic localization of
monomeric a-syn, it is possible that disruption of the physiological
interaction of a-syn with lipid rafts may result in changes in a-syn
that contribute to the pathogenesis of PD [62].
Moreover, Ab [80] and a-syn oligomers [47,81,82] are known
to interact with membrane-like lipids and to form ring-like
structures [1,7,41,48,83]. For example, in the case of a-syn,
interactions with brain membranes [26] or phospholipid bilayers
or vesicles that model biological membranes results in conforma-
tional modifications that facilitate oligomerization and formation
of ring-like assemblies [41,64,84]. It is also important to note that
while interaction of a-syn with biological membranes may inhibit
the formation of fibrils and protofibrils [84], membrane interac-
tion facilitates the formation of lower order oligomers because it
promotes the docking of the propagating dimers [4]. In support of
this, Giannakis et al recently showed that a-syn dimers
preferentially bind lipid membranes, while trimers and tetramers
were also detected on the lipid surface [42]. More detailed studies
of the structure and organization of these aggregates have been
sparse because of the difficulties in producing microcrystals of the
oligomers suitable for X-ray analysis. Because of the inherent
limitations in elucidating the precise structure of such transient
intermediate species as oligomers, most studies have focused on in
silico analyses [85].
The simulations and modeling in the present study suggest that
anchoring of propagating a-syn complexes with Ab to the
membrane facilitates the incorporation of additional a-syn
monomers, leading to the formation of trimers, tetramers,
pentamers, and hexamers—the latter oligomers forming ring-like
structures. The hybrid multimers of Ab and a-syn might embed in
the membrane, leading to the formation of nanopore-like
structures resulting in abnormal ion conductance.
Previous studies have shown that Ab penetrates in the
membrane and aggregates to form channels that facilitate the
abnormal trafficking of cations such as Ca
2+ and K
+ [29,86–88].
Studies of a-syn aggregation by atomic force microscopy have
shown that the oligomers form heterogeneous pore-like structures
that might induce cell death via disruption of calcium homeostasis
[49,50]. This is in agreement with the present study showing that
the hetero-multimers of Ab and a-syn promote abnormal calcium
influx. Moreover, recent studies have shown that helical a-syn
forms highly conductive ion channels [89] and human neuronal
cells expressing mutant a-syn have high plasma membrane ion
permeability sensitive to calcium chelators [30] and that cells
transduced with a-syn display significant increases in Zn
2+-
sensitive ion channel activity that might correspond to Zn
2+-
sensitive non-selective cation channels [4]. Taken together, these
results support the contention that Ab and a-syn aggregates might
form functional ion-permeable channels that might play a role in
the mechanisms of neurodegeneration in LBD.
There is growing evidence that pathological interactions among
misfolded molecules might play an important role in the formation
of neurotoxic oligomers that accumulate in AD, LBD and other
dementias. Remarkably, Ab has also been shown to promote the
accumulation of Tau [90], a microtubule binding protein present in
the tangles in AD and fronto-temporal dementia (FTD), and the C-
terminus of a-syn has been shown to interact with Tau under
abnormal conditions [91]. Along these lines, our molecular
dynamics studies showed that the termini of the Ab molecule
recognize specific aa in different regions of the two a-syn molecules.
Interestingly, aa residues in the C-terminus of Ab interact primarily
with residues in the N-terminus of the first a-syn molecule (aa 3–33,
Table 1), which is consistent with a previous study identifying a
novel Ab-binding domain within residues 1–56 of a-syn [92]. The
N-terminus of Ab favors interaction with residues primarily in or
near the non-amyloid component (NAC) region of the second a-syn
molecule (aa 88, 91, 92 and 95, Table 1), which is consistent with
previous biochemical data [93]. The misfolded Ab monomers and
dimers might serve as a bridge across a-syn dimers and trimers,
increasing the stability of the oligomers and the formation of ring-
like structures in the membrane.
In conclusion, the present study showed that Ab and a-syn
interact in vivo in the brains of patients with LBD and in tg mice
and that these interactions might result in the formation of stable
hybrid ring-like oligomers in the membranes accompanied by
abnormal channel activity. Therefore, developing strategies that
might prevent Ab and a-syn interactions might represent a viable
target for the development of approaches for the treatment of
combined AD and PD. Moreover, this study brings to light the
concept of the formation of hybrid oligomers and their role in the
pathogenesis of neurodegenerative disorders. Similar interactions
among other heterogeneous proteins such as prion protein,
huntingtin, A-Bri, and tau might be at play in other disorders of
protein misfolding.
Materials and Methods
Molecular dynamics simulations and modeling of a-syn
and Ab
The modeling and simulations were based on the previously
reported NMR structure of a-syn (PDB index 1xq8 [94]) and Ab
(PDB index 1IYT). The molecules were then minimized for 10,000
iterations of steeped descent with the Discover program (Accelrys,
San Diego, CA). Molecular dynamics simulations of a-syn and Ab
molecules were conducted using periodic boundary conditions at
constant pressure (1 atm) and temperature (310 K) with the water
boxinwhich the shortestdistancebetweentheproteinmoleculeand
the box walls was 30A ˚. The NAMD molecular dynamics program
version 2.5 [95] was used with the CHARMM27 force-field
parameters [96] to simulate the behavior of a-syn and Ab molecules
in water under normal conditions and the interaction of the POPC
membrane with the a-syn aggregates. The temperature was
maintained at 300 K by means of Langevin dynamics using a
collision frequency of 1/ps. A fully flexible cell at constant pressure
(1 atm) was employed using the Nose ´-Hoover Langevin Piston
algorithm [97,98] as used in the NAMD software package.
Initial coordinates were taken from a previously equilibrated
500 ps system. The van der Waals interactions were switched
smoothly to zero over the region 10A ˚ and electrostatic interactions
were included via the smooth particle-mesh Ewald summation
[99]. The impulse-based Verlet-I/r-RESPA method [100,101]
was used for multiple time-stepping: 4 fs for the long-range
electrostatic forces, 2 fs for short-range nonbonded forces, and 1 fs
for bonded forces. The simulation was done in four steps. Initially
the system of protein and water molecules was minimized for
10,000 iterations. Then the system was heated in 0.1u increments
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simulation was conducted. Data for analysis were taken between
50 ps and 5 ns of the simulation.
Ab and a-syn interactions and docking to the membrane
Interactions between Ab and a-syn monomers, dimers, and
trimers, were studied using the programs Hex 4.5 [102,103] and
the docking module of Insight II (Accelrys) with a 1A ˚ grid and cut-
off distance of 20A ˚. Taking into account previous studies [82]
showing that a-syn and Ab aggregation occurs on the membrane,
we also studied docking of molecules on a flat surface representing
the plasma membrane as previously described [4]. We also
simulated the behavior of pentamers formed from a-syn with Ab
on the POPC membrane. The explicit (all-atom) membrane
models were utilized for simulation. Because the docking
configurations of the proteins were mostly open to solution, we
used a dielectric constant of 16 to calculate the electrostatic energy
for a-syn and Ab docking.
For predicting membrane-contacting surfaces of proteins we
developed the program MAPAS, based on calculations of
membrane-association scores for proteins and protein aggregates
[104]. This program was applied to intermediate a-syn and Ab
conformers and top scoring predicted membrane attractive
surfaces were used to dock the protein molecules and to
subsequently calculate possible a-syn–a-syn and a-syn–Ab docking
configurations on the membrane. Low energy a-syn/a-syn
propagating complexes were used in simulations of consecutive
docking of the next a-syn molecules. To estimate the possible
surface of the a-syn dimer contact with the membrane that
changes during MD simulations we measured the angle between
the C-alpha atoms of three residues: VAL66 (a-syn1), LYS45 (a-
syn1), VAL37 (a-syn2) using the InsightII program (Accelrys) for
each 10 ps MD conformation of the a-syn dimer.
In order to investigate the dynamics of Ab/a-syn interactions
when the molecules are separated by a membrane, we also
conducted MD simulations of the system containing one Ab
molecule (2 ns conformer) on one side of the membrane, and one
a-syn molecule (4.5 ns conformer) on the other side of the
membrane. We also conducted MD simulations of the system
containing the a-syn pentamer with Ab molecule docked to the
one of the a-syn–a-syn interfaces and the POPC membrane. The
pentamer of the a-syn molecules was constructed by minimal
energy docking of the 4 ns conformers of a-syn (as described in our
previous publication [4]). The Ab molecule (2 ns MD conformer
from the previous MD simulation of Ab in water) has been docked
to the minimal energy position in the interface between two a-syn
molecules. The between two a-syn pentamer complexed with the
Ab monomer was located on the surface of the membrane with the
shortest contacts between the protein docked to the membrane in
the range of 3A ˚. The explicit (all-atom) POPC membrane model
was utilized for simulation. The simulation was done in four steps.
Initially the system of protein, membrane, and water molecules
was minimized for 10,000 iterations. Then the system was heated
in 0.1u increments and equilibrated for 500 ps; then the MD
simulation was conducted using periodic boundary conditions at
constant pressure (1 atm) and temperature (310 K) with the water
box in which the shortest distance between the protein molecule
and the box walls was 30A ˚. The NAMD molecular dynamics
program version 2.5 [95] was used with the CHARMM27 force-
field parameters [96]. The temperature was maintained at 300 K
by means of Langevin dynamics using a collision frequency of 1/
ps. A fully flexible cell at constant pressure (1 atm) was employed
using the Nose ´-Hoover Langevin Piston algorithm [97,98] as used
in the NAMD software package. The van der Waals interactions
were switched smoothly to zero over the region 10A ˚ and
electrostatic interactions were included via the smooth particle-
mesh Ewald summation [99]. The impulse-based Verlet-I/r-
RESPA method [100,101] was used for multiple time-stepping:
4 fs for the long-range electrostatic forces, 2 fs for short-range
nonbonded forces, and 1 fs for bonded forces. Data for analysis
were taken each 10 ps of the simulation.
Immunoprecipitation assays
Briefly, homogenates from human brains and transgenic mice
were lysed in buffer A (20 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1 mM EDTA, 1 mM NaVO4, 50 mM NaF, with protease
inhibitors (Roche, Basel, Switzerland)) containing 1% Triton X-
100. Immunoprecipitation assays were carried out essentially as
previously described [105]. The lysates were then centrifuged for
20 min for 12,000 rpm, and the protein concentrations were
determined with a BCA protein assay kit. Three hundred mg of the
supernatants was incubated with 1 mg of polyclonal antibody
against a-syn (Cell Signaling, Danvers, MA) overnight at 4uC, and
then the immunocomplexes were adsorbed to protein A-Sepharose
4B (Amersham, Piscataway, NJ). After washing extensively with
buffer A containing 1% Trion X-100, samples were heated in SDS
sample buffer for 5 min and subjected to gel electrophoresis on
tris-tricine gels followed by immunoblot analysis with an antibody
against a-syn (Cell Signaling) or Ab (6E10, Signet Laboratories,
Dedham, MA). Also samples were immunoprecipitated with an
antibody against Ab (6E10), and run on a Bis-Tris 4–20% gel
followed by immunoblot analysis with a mouse monoclonal
antibody against a-syn (BD, Franklin Lakes, NJ).
Tissue samples
A total of 12 cases (n=4 non demented controls; n=4
Alzheimer’s Disease and n=4 dementia with Lewy bodies-
DLB) from the ADRC at UCSD were included for immunoblot
analysis. All cases were carefully characterized clinically and
neuropathologically and had lees than 8 hrs postmortem. The
most common cause of death was bronchopneumonia and sepsis
followed by renal and heart failure. The diagnosis of AD was
based on the Consortium to Establish a Registry for AD (CERAD)
and National Institute of Aging (NIA) criteria for diagnosis
[106,107]. The diagnosis of DLB was based on the clinical
presentation of dementia and the pathological findings of Lewy
bodies (LBs) detected using anti-ubiquitin and anti-a-syn antibod-
ies as recommended by the Consortium on DLB criteria for a
pathologic diagnosis of DLB [107]. In addition to the presence of
LBs, the DLB cases had abundant plaques in the neocortex and
limbic system but fewer tangles compared to AD cases. The DLB
group belongs to a more general heterogeneous group of
conditions with dementia and parkinsonism denominated Lewy
body disease (LBD).
For studies in animal models, brain samples from 16 mice (n=4
nontg; n=4 APP tg; n=4 2a-syn tg and n=4 APP/a-syn double
tg mice were included for immunoblot analysis. For this purpose,
6-month old nontg, single (APP or a-syn tg) and double tg (APP/a-
syn tg) mice were utilized. The characteristics of thy1-APPmut tg
(line 41) [108] and PDGFb-a-syn tg mice (line D) [109], have been
previously described. The APP tg mice express mutated (London
V717I and Swedish K670M/N671L) human APP751 under the
control of the murine Thy1 promoter (Thy1-hAPP, line 41) [108].
This tg model was selected because mice produce high levels of
Ab1–42 and exhibit performance deficits in the water maze,
synaptic damage, and plaque formation at an early age (beginning
at 3 months) [108,110]. Heterozygous APP and 2a-syn tg mice
were crossed as described before [31] to obtain double tg animals.
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mice with non-tg C57BL/66DBA/2 F1 breeders. All mice were
heterozygous with respect to the transgene.
Immunoblot analysis
To analyze the distribution and levels of a-syn and Ab in the
brains of patients with DLB and in tg mice, briefly as previously
described, samples from the frontal cortex were homogenized and
fractioned into cytosolic and membrane fractions by ultracentri-
fugation. Approximately 20 mg of protein per lane were loaded
into 4–12% Bis-Tris gels with 3-{N-morpholino] propanesulfonic
acid (MOPS)/SDS buffer and blotted onto polyvinylidene fluoride
(PVDF) membranes. Blots were incubated with antibodies against
Ab (6E10, 1:1000, Signet) and a-syn (1:1000, Chemicon,
Temecula, CA), followed by secondary antibodies tagged with
horseradish peroxidase (HRP, 1:5000, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) and visualized by enhanced chemilumines-
cence and analyzed with a Versadoc XL imaging apparatus
(BioRad, Hercules, CA). Analysis of actin levels was used as a
loading control.
To determine the effects of Ab on a-syn aggregation,
recombinant a-syn (1 mM, Calbiochem, San Diego, CA) was
incubated in the presence or absence of freshly-solubilized or
aggregated Ab1–42 (10–20 mM, American Peptide, Sunnyvale, CA)
at 37uC for 16 h {Hashimoto, 1998 #2038}. Additional
experiments were performed by incubating recombinant a-syn
(10 mM, Calbiochem) with wildtype (1–17) or mutated Ab
peptides (PHE4SER, GLU11ARG, VAL12SER, LYS16ASP)
(custom-made by Invitrogen, Carlsbad, CA) at 20 mM followed
by immunoblot analysis with the mouse monoclonal antibody
against a-syn (LB509, 1:1000, Zymed Laboratories, San Fran-
cisco, CA) or Ab (6E10) as previously described [111] and
analyzed in the VersaDoc imaging system using the Quantity One
software (BioRad, Hercules, CA).
Lipid monolayer assay
A synthetic lipid monolayer was generated as described by Ford,
M. et al. [112]. Briefly, cholesterol, phosphatidylethanolamine and
phosphatidylcholine (all from Sigma) were dissolved in chloroform
at a concentration of 10 mg/mL. Phosphatidylinositol-4,5-bipho-
sphate (also from Sigma) was dissolved at 1 mg/mL in 3:1
chloroform:methanol. Lipid stocks were stored at 280uC. A
monolayer of lipid containing 10% cholesterol, 40% phosphatidyl-
ethanolamine, 40% phosphatidylcholine and 10% phosphatidyli-
nositol-4,5-biphosphate (at a final concentrationof 0.1 mg/mL) in a
19:1mixtureofchloroformmethanolwasformed onthe surfaceofa
100 mM Tris/HCl/1 mM dithiothreitol buffer droplet in a Teflon
block (kind gift of Dr. Harvey McMahon). After 1 hr incubation at
room temperature, a carbon-coated gold electron microscopy grid
[gold/mesh 100 formvar carbon film (EMS, Hatfield, PA)] was
placed onto the monolayer and 10 mM recombinant a-syn
(Calbiochem); 10 mMA b1–42 (American Peptide) alone or an
equimolar mixture of both proteins were introduced into the buffer.
After 6 hrs incubation at room temperature in a humid chamber,
the grid was removed and stained with uranyl acetate (1% uranyl
acetate) for 5 min and 2% bismuth subnitrate for 3 min, and
analyzed by electron microscopy.
Electron microscopy studies of a-syn and Ab aggregates
To investigate the ultrastructural characteristics of the Ab/a-syn
aggregates, 1 ml aliquots of a-syn alone or in combination with Ab
prepared under identical conditions as for immunoblotting were
pipetted onto formvar coated grids, followed by 2% uranyl acetate
staining. Grids were analyzed with a Zeiss OM 10 electron
microscope as previously described [111]. To estimate the number
of ring-like structures formed, 10 random fields were analyzed at
50,0006 magnification per condition. For each condition, three
different grids were analyzed. The average number of ring-like
structures was analyzed with digitized images using the ImageJ
program (NIH). In each case a minimum of 100 rings was included
for analysis. Results were expressed as mean per 1000 nm
2.
Preparation and electrophysiological analysis of cells
expressing a-syn and treated with Ab
HEK293T cells were grown on 25-mm coverslips at 50%
confluence and were incubated with lentiviruses expressing a-syn or
GFP(eachat1.0610
7 TU)in10%fetalcalf serum(FCS)for24 h at
37uC, 5% CO2. Lentiviruses were prepared as previously described
[113]. The cells were then washed with phosphate-buffered saline
(PBS) and incubated in DMEM with 10% FCS for an additional 4
days. The efficiency of transduction of lenti-GFP was more than
90%. For electrophysiological measurements, whole-cell cation
currents were recorded with an Axopatch-1D amplifier and a
DigiData 1200 interface (Axon Instruments, Sunnyvale, CA) using
patch-clamp techniques. Patch pipettes (2–3 MV) were fabricated
on a Sutter electrode puller using borosilicate glass tubes and fire
polished on a Narishige microforge. Command voltage protocols
and data acquisition were performed using pCLAMP-8 software
(Axon Instruments). All experiments were performed at room
temperature (22–24uC). The ionic composition of the external
solution was (in mM): NaCl 145, KCl 5, MgCl2 1, CaCl2 2, glucose
10, and HEPES 10 (pH=7.4). During patch-clamp recording,
tetrodotoxin (0.1 mM) and CdCl2 (0.1 mM) were added to the
external solution to block voltage-dependent Na
+ and Ca
2+
channels. The ionic composition of the pipette solution was (in
mM): CsCl 150 and HEPES 10 (pH=7.2). The current-voltage (I–
V) relationship was determined by a step voltage protocol of 50 ms
duration. The cell was held at 250 mV and stepped to levels
between 280 mV and +80 mV in 20-mV increments.
For verification of a-syn expression after lentivirus infection,
transduced cells were harvested in lysis buffer and analyzed by
immunoblot with an antibody against a-syn (1:1000, Chemicon).
For immunocytochemistry, cells were cultured on cover slips until
50% confluence and treated as described above, fixed in 4%
paraformaldehyde for 20 min, and blocked overnight at 4uCi n
10% FCS and 5% bovine serum albumin. Cells on coverslips were
then incubated overnight at 4uC with the antibody against a-syn
(1:2500, Chemicon). The following day, the antibody was detected
with the Tyramide Signal Amplification-Direct (Red) system (NEN
Life Sciences). Coverslips were air dried overnight, mounted on
slides with anti-fading media (Vectashield, Vector Laboratories,
Burlingame, CA), and imaged with the laser scanning confocal
microscope (LSCM, MRC1024, BioRad). Co-localization with
GFPwasvisualized withtheendogenousgreenfluorescenceofGFP.
Calcium mobilization assay
Assessment of calcium influx was carried out using a modified
protocol of the FLIPR 4 calcium assay (Molecular Devices,
Sunnyvale, CA). Briefly, HEK293T cells were infected with
lentiviral constructs harboring human wt a-syn (lenti-a-syn) or no
extra DNA (lenti-empty). Cells infected at a MOI of 30 were
cultured inDMEMmedium(Mediatech,Manassas, VA)containing
10%FBS and penicillin/streptomycin. Cultures were maintained in
an incubator at 37u C, in an atmosphere of 95% air and 5% CO2.
Two days after infection, cells were plated at a density of
30,000 cells/well on Costar 96 well-black plates with flat clear
bottom (Corning, Corning, NY). Cells were treated for 24 hr with
control vehicle or freshly solubilized Ab1–42 (10 mM American
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buffer and 100 ml of calcium dye was added to each well. Cells were
kept in the incubator at 37uC for 1 hr before measuring
fluorescence with excitation/emission filter at 470–495/515–
575 nm on a DTX 880 Multimode Detector (Beckman Coulter,
Fullerton, CA). As a positive control of calcium influx, 0.6 mgo f
ionomycin (Sigma, St. Louis, MO) was added to the indicated wells.
Statistical analysis
The data are expressed as mean values6standard error of the
mean (SEM). Statistical analysis was performed using one-way
analysis of variance (ANOVA) followed by post hoc Dunnett’s or
Tukey-Kramer tests (Prism Graph Pad Software, San Diego, CA,
USA). The significance level was set at p,0.05.
Supporting Information
Figure S1 Molecular dynamics simulations of Ab conformers at
various time points. (A) Initial conformer; (B) 0.5 ns conformer; (C)
1.0 ns conformer; (D) 1.5 ns conformer; (E) 2.0 ns conformer; (F)
2.5 nsconformer;(G)3.0 nsconformer;and (H)superimposed image
showing all conformers in a composite image.
Found at: doi:10.1371/journal.pone.0003135.s001 (0.69 MB TIF)
Figure S2 Molecular dynamics simulations showing the changes
in Ab secondary structure over time. The first time zero line shows
the amino acid sequence of Ab1–42, and the remaining lines
depict the secondary structural characteristics.
Found at: doi:10.1371/journal.pone.0003135.s002 (0.86 MB TIF)
Figure S3 Molecular dynamics simulations of a-syn multimers
with Ab monomers and dimers. The 4 ns a-syn dimer and the 2 ns
Ab conformer were used for modeling all complexes. (A) Structural
organization of one a-syn dimer complexed with one Ab monomer.
(B) Structural organization of one a-syn trimer complexed with two
Ab monomers. (C) Structural organization of one a-syn pentamer
complexed with two Ab monomers. (D) Structural organization of
one a-syn dimer complexed with one Ab dimer. (E) Structural
organization of one a-syn trimer complexed with one Ab dimer. (F)
Structural organization of one a-syn pentamer complexed with one
Ab dimer.
Found at: doi:10.1371/journal.pone.0003135.s003 (1.04 MB TIF)
Figure S4 Increased levels of a-syn multimers in the presence of
Ab under in vitro aggregating conditions. Freshly-solubilized
recombinant a-syn (10 mM) and freshly-solubilized Ab (5–20 mM)
were incubated together at the indicated ratios for 24 hrs and
analyzed by immunoblot. (A) Incubation of a-syn with Ab
promotes the formation of a 170-kDa oligomer of a-syn. (B)
Semi-quantitative analysis of a-syn multimer levels showing
increasing levels of a-syn dodecamer with increasing Ab
concentration. In cases where no a-syn recombinant protein was
included (negative control), no immunoreactivity was detected
with the antibody against a-syn.
Found at: doi:10.1371/journal.pone.0003135.s004 (0.28 MB TIF)
Figure S5 Analysis of intracellular calcium levels in cells
expressing a-syn and treated with Ab. 293T cells were infected
with lenti-vector or lenti-a-syn for two days and treated with
10 mM freshly-solubilized Ab1–42 for 24 hrs, followed by
treatment with calcium dye and analyzed by fluorescence
microscopy and with a spectrophotomer. (A) Minimal calcium
dye uptake in cells infected with vector control. (B, C) Moderate
calcium dye uptake in cells expressing a-syn (B) or exposed to Ab
(C). (D) High calcium dye uptake in cells expressing a-syn and
treated with Ab. (E) Levels of calcium dye uptake, expressed in
terms of relative fluorescence units (RFU). *P,0.05 compared to
vector-infected controls (by one-way ANOVA with post-hoc
Dunnett’s test); **P,0.05 compared to cells expressing a-syn or
treated with Ab alone (by one-way ANOVA with post-hoc Tukey-
Kramer test).
Found at: doi:10.1371/journal.pone.0003135.s005 (0.38 MB TIF)
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